Meta AnalysisID 6616
紫龙金片联合化疗治疗非小细胞肺癌的效果：随机对照试验的系统评价与Meta分析
CRD42020162177
chemotherapy often causes many serve adverse reactions, such as myelosuppression, nausea and vomiting. Patients with NSCLC may be discouraged from chemotherapy because of them.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6616
- Evidence Id
- 15174
- Core Evidence Id
- 15174
- Source Meta Analysis Id
- 6596
- Herb2 Meta Analysis Id
- HBMA006596
- Crd Id
- CRD42020162177
- Title
- The Effect of Zilongjin Tablets combined with chemotherapy in the treatment of non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials
- Review Question
- chemotherapy often causes many serve adverse reactions, such as myelosuppression, nausea and vomiting. Patients with NSCLC may be discouraged from chemotherapy because of them.
- Study Type Included
- All patients in control group were mainly treated with chemotherapy whose regimen was not limited. The patients in the experimental group were treated with chemotherapy combined with Zilongjin tablets whose intervention must be guaranteed as the only variable.
- Condition Being Studied
- In the classification of lung cancer, non-small cell lung cancer (NSCLC) accounts for about 85%. Because most patients are diagnosed with NSCLC in advanced stage, platinum-based chemotherapy is the main treatment . However, fatally, chemotherapy often causes many serve adverse reactions, such as myelosuppression, nausea and vomiting. Patients with NSCLC may be discouraged from chemotherapy because of them. There is no doubt that something should be found to solve this problem.
- Participant
- Participants were selected with the pathological diagnosis which was belong to NSCLC without limitations on region, age, and gender.
- Animal
- Human Disease Modelled
- Intervention
- Zilongjin Tablets combined with chemotherapy
- Comparator Control
- chemotherapy
- Main Outcome
- 1.the solid tumor effect, Measures of effect ORR and DCR according to WHO or RECIST standard
- Outcome Measure
- Additional Outcome
- 1.the improvement in the quality of life, 2.the reduction in adverse effects rate Measures of effect 1.KPS 2.adverse effects according to WHO standard.
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Tablets; zilongjin
- Contact
- Jixin Chen [email protected]
- Organisational Affiliation
- Funding Source
- the National Natural Science Foundation of China (81974543)
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2019-12-12
- Registration Date
- 2020-04-28
- Anticipated Start Date
- 2019-12-08
- Anticipated Completion Date
- 2020-01-10
- Title Cn
- 紫龙金片联合化疗治疗非小细胞肺癌的效果：随机对照试验的系统评价与Meta分析
- Title En
- The Effect of Zilongjin Tablets combined with chemotherapy in the treatment of non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials
- Bilingual Status
- complete